In order to determine that DDR deficiency was associated with EGFR exon 19 deletion, we first studied cell survival in response to cisplatin (DNA cross‐linking drug) in both NSCLC cell lines and NIH3T3 MEFs expressing either wild‐type EGFR or EGFR harboring exon 19 deletion mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.